3Q Revenues: $6.4 billion (+12%)
3Q Earnings: $2.0 billion (+3%)
YTD Revenues: $18.8 billion (+9%)
YTD Earnings: $5.6 billion (-8%)
Comments: Product sales increased 12% globally, driven by 18% volume growth across a number of our newer products, including Otezla, MVASI, KANJINTI, and Repatha, partially offset by declines in select products from the impact of COVID-19, and biosimilar and generic competition. Prolia sales increased 11% to $701 million. EVENITY generated $59 million of sales in the quarter. Repatha sales increased 22% to $205 million. Aimovig sales increased 59% to $105 million. Parsabiv sales increased 17% to $183 million. Otezla generated $538 million of sales in the quarter. Enbrel sales decreased 3% to $1.3 billion. AMGEVITA increased 31% to $80 million. KYPROLIS sales decreased 2% to $260 million. XGEVA sales increased 1% to $481 million. Vectibix sales declined 2% to $193 million. Nplate sales increased 9% to $212 million. BLINCYTO sales increased 5% to $89 million. MVASI generated $231 million of sales in the quarter. KANJINTI generated $167 million of sales in the quarter. Neulasta sales decreased 22% to $555 million due to increased biosimilar competition. EPOGEN sales decreased 31% to $149 million. Aranesp sales decreased 15% to $384 million driven by lower net selling price and competition. Sensipar/Mimpara sales decreased 64% to $39 million due to generic competition.
